What is Lifesci Capital's Estimate for Immunome Q1 Earnings?

Key Points

• Lifesci Capital has raised its Q1 2026 earnings per share (EPS) forecast for Immunome to ($0.73), slightly improving from a prior estimate of ($0.75). The company's full-year earnings consensus estimate stands at ($2.21) per share.
• Immunome reported a ($0.50) EPS for the latest quarter, exceeding consensus expectations by $0.02, with revenue reaching $4.02 million against anticipated $1.03 million.
• Analysts have varied ratings on Immunome, with an average price target of $23.14 and a consensus rating of "Moderate Buy," while other reports indicate a recent increase in institutional investment activity.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Equities research analysts at Lifesci Capital increased their Q1 2026 earnings per share estimates for shares of Immunome in a report issued on Wednesday, August 6th. Lifesci Capital analyst C. Zhu now expects that the company will earn ($0.73) per share for the quarter, up from their previous estimate of ($0.75). The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q2 2026 earnings at ($0.73) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.02. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. The company had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. cut their target price on Immunome from $23.00 to $22.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Wedbush restated an "outperform" rating and issued a $21.00 target price on shares of Immunome in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $23.14.

Immunome Stock Performance

NASDAQ IMNM traded up $0.26 during trading hours on Monday, hitting $10.20. The company had a trading volume of 127,631 shares, compared to its average volume of 1,011,431. Immunome has a 52 week low of $5.15 and a 52 week high of $16.73. The firm has a 50 day simple moving average of $9.61 and a 200 day simple moving average of $8.92. The firm has a market capitalization of $887.46 million, a price-to-earnings ratio of -3.31 and a beta of 1.93.

Hedge Funds Weigh In On Immunome

A number of large investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 37.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after buying an additional 2,054,640 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company's stock valued at $36,081,000 after buying an additional 533,161 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Immunome by 43.4% during the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock valued at $28,987,000 after buying an additional 1,303,753 shares in the last quarter. EcoR1 Capital LLC raised its holdings in shares of Immunome by 5.2% during the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company's stock valued at $27,454,000 after buying an additional 200,000 shares in the last quarter. Finally, Enavate Sciences GP LLC purchased a new position in shares of Immunome during the 4th quarter valued at about $36,939,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Jean Jacques Bienaime acquired 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were bought at an average cost of $9.38 per share, with a total value of $46,900.00. Following the acquisition, the director owned 36,415 shares in the company, valued at approximately $341,572.70. This represents a 15.92% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.69% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.